Abstracts tagged "giant cell arteritis"

Abstract Number: 2400 • ACR Convergence 2023
Applanation Tonometry of the Temporal Arteries in Participants with Suspected Giant Cell Arteritis: A Proof of Concept
Jean-Paul Makhzoum¹, Stephanie Ducharme-Benard², Samer Hussein², Rosalie-Selene Meunier², Carolyn Ross³, Alik Chamlian⁴, Jonathan Ducharme⁵, Leia Chamlian⁴, Alae Dhahbi⁴, Christian Pagnoux⁶ and Remi Goupil⁷, ¹Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Canadian Network for Research on Vasculitides, Montreal, QC, Canada, ²Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ³Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁴Laval University, Montreal, QC, Canada, ⁵University of Sherbrooke, Montreal, QC, Canada, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷Hopital du Sacre-Coeur de Montreal, University of Montreal, Montreal, QC, Canada
Background/Purpose: Applanation tonometry (ATn) is a non-invasive, point-of-care tool used to capture arterial pressure waveforms. It can measure arterial pulse wave velocity (PWV), a marker…
Abstract Number: 2418 • ACR Convergence 2023
Effectiveness of Dose Spacing with Tocilizumab in Giant Cell Arteritis Treatment
Sharon Cowley¹, Colm Kirby², Patricia Harkins³, Richard Conway⁴, Grainne Murphy⁵ and David Kane⁶, ¹Tallaght University Hospital, Dublin, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Ireland, ³St James's Hospital, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Cork University Hospital, Cork, Ireland, ⁶Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: The only steroid sparing agent approved for treatment of Giant Cell Arteritis (GCA) is the anti-interleukin-6 receptor antagonist tocilizumab. There remains uncertainty regarding treatment…
Abstract Number: 2603 • ACR Convergence 2023
Impact of IL-6 Receptor Small Nucleotide Polymorphism Asp358Ala on T Cell Activity and Clinical Outcomes in Patients with Giant Cell Arteritis
Christopher Redmond¹, Robert Zorc², McKella Sylvester³, Cameron Rankin⁴, Rebecca Kuan⁵, Kristina Wells⁶, Lily Dai⁷, Kaitlin Quinn⁸, Massimo Gadina⁹ and Peter Grayson¹⁰, ¹National Institutes of Health, Hagerstown, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health, Bethesda, MD, ³Colgate University, Bethesda, MD, ⁴NIAMS, NIH, Washington, DC, ⁵NIH, Bethesda, MD, ⁶University of California Davis, Bethesda, MD, ⁷NIH, Germantown, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ¹⁰National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis in adults that commonly involves the aorta and branching arteries, resulting in multiple symptoms including…
Abstract Number: 0800 • ACR Convergence 2023
CD4+ CD96+ T Cells Are Pathogenic Effector Cells in Giant Cell Arteritis
Shozo Ohtsuki¹, Jose Morales², Yuki Sato², Chenyao Wang², Matthew Koster³, Kenneth Warrington³, Gerald J. Berry⁴, Jorg Goronzy³ and Cornelia M. Weyand⁵, ¹Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Stanford University School of Medicine, Stanford, CA, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: In Giant Cell Arteritis (GCA), granulomatous infiltrates occupy the vessel wall and elicit maladaptive vascular remodeling with intimal hyperplasia. The major cell types of…
Abstract Number: 1889 • ACR Convergence 2023
Utility of a Diagnostic Algorithm in the Assessment of Large Vessel Vasculitis
HUGO AVALOS BOGADO¹, GUSTAVO AÑEZ STURCHIO², Ernesto Trallero-Araguas³, Esther Espartal López⁴, sebastián Sandoval Moreno¹, daniela Ulloa Navas⁵ and Juan José De Agustín De Oro², ¹Rheumatology Department Vall d'Hebrón University Hospital, Barcelona, Spain, ²Vall d'Hebron University Hospital, Barcelona, Spain, ³Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ⁴Vall Hebron University Hospital, Rheumatology Department, Barcelona, Spain, ⁵Rheumatology Department, Vall Hebron University Hospital, Barcelona, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most prevalent type of primary systemic vasculitis among individuals aged 50 and above. Imaging techniques such as ultrasound…
Abstract Number: 2401 • ACR Convergence 2023
A Study Defining the Optimal Sonographic Parameters for Intima-Media Thickness in Diagnosing Giant Cell Arteritis
Colm Kirby¹, Sharon Cowley², Rachael Flood¹, Ronan Mullan¹, Grainne Murphy³ and David Kane⁴, ¹Tallaght University Hospital, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Ireland, ³Cork University Hospital, Cork, Ireland, ⁴Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: In recent years, Temporal Artery US (TAUS) incorporating Axillary Artery US (AAUS) has become a reliable alternative to biopsy for diagnosing GCA but studies…
Abstract Number: 2419 • ACR Convergence 2023
Visual Manifestations in Giant Cell Arteritis: Identification of Risk Factors from the ARTESER Registry
Juan Molina-Collada¹, Marta Domínguez², Rafael Benito Melero-Gonzalez³, Elisa Fernandez-Fernandez⁴, Maria. T Silva-Diaz⁵, Joaquín M. Belzunegui⁶, Ismael González⁷, Julio Sanchez Martin⁸, Javier Narvaez⁹, Eva Galíndez¹⁰, javier Mendizábal¹¹, Leticia Leon Mateos¹², Javier Loricera⁸, Alejandro Muñoz¹³, Santos Castañeda¹⁴, Iván Castellvi¹⁵, Marina Tortosa-Cabañas¹⁶, Vanesa Navarro¹⁷, Carlos Galisteo¹⁸, Ivette Casafont-Solé¹⁹, Jose Andres Roman Ivorra²⁰, TAREK CARLOS SALMAN MONTE²¹, Margarida Rocha²², Carlota Laura Iñiguez²³, Maria Vanesa Hernandez Hernandez²⁴, Cristina Campos²⁵, María Alcalde²⁶, Antonio Juan Mas²⁷, Francisco Javier Prado²⁸ and Ricardo Blanco²⁹, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³CHU Vigo, O Carballino, Spain, ⁴La Paz University Hospital, Madrid, Spain, ⁵Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Hospital Universitario Donostia, Donostia, Spain, ⁷Hospital Universitario de León, León, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Hospital Universitario de Basurto, Bilbao, Spain, ¹¹Complejo Hospitalario de Navarra, Pamplona, Spain, ¹²IDISSC Hospital Clinico San Carlos, Madrid, Spain, ¹³Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Spain, ¹⁵Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ¹⁶Ramon y Cajal University Hospital, Madrid, Spain, ¹⁷H Moisès Broggi, Sant Joan Despí, Barcelona, Spain, ¹⁸Hospital Universitario Parc Taulí, Barcelona, Spain, ¹⁹Hospital Germans Trias i Pujol, Badalona, Spain, ²⁰Hospital Universitari i Politècnic la Fe, Valencia, Spain, ²¹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²²Osakidetza, Bilbo, Spain, ²³Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁴Hospital Universitario de Canarias, La Laguna, Spain, ²⁵Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ²⁶Hospital Severo Ochoa, Madrid, Spain, ²⁷Hospital Universitario Son Llàtzer, Mallorca, Spain, ²⁸Research department Hospital Infantil de México Federico Gómez, Mexico City, Mexico, ²⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Visual loss is one of the most feared complications in giant cell arteritis (GCA). Some factors have been previously associated with visual loss, as…
Abstract Number: 1040 • ACR Convergence 2023
Impact of Ultrasound Limitation to Assess Aortitis in Patients with Giant Cell Arteritis: Comparative Study with FDG-PET/CT
Juan Molina-Collada¹, Isabel Castrejon², Irene Monjo³, Elisa Fernandez-Fernandez⁴, Gabriela Torres⁵, JULIA MARTINEZ BARRIO⁶, Jose María Alvaro-Gracias⁷ and Eugenio De Miguel⁵, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Hospital Universitario Gregorio Marañón, Madrid, Spain, ³University Hospital La Paz, Madrid, Spain, ⁴La Paz University Hospital, Madrid, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁷Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Aortitis is a serious potential complication of patients with giant cell arteritis (GCA) and may lead to dilation, aneurysms or dissection. Since ultrasound (US)…
Abstract Number: 2085 • ACR Convergence 2023
A Survey on Giant Cell Arteritis-Related Knowledge Among Internal Medicine Residents
Helina Maharjan¹, Muhammad Abdullah², Summia Matin Afridi³, Alsayed Osman⁴, Aleena Sammar⁵ and Ahmad Raja⁶, ¹Bassett Medical Center, Cooperstown, NY, ²Islamic International Medical College, Rawalpindi, Pakistan, ³Albany Medical Center, Albany, NY, ⁴AdventHealth Florida, Orlando, FL, ⁵Parkview Medical Center, Pueblo, CO, ⁶Mary Imogene Bassett Hospital, Evanston, IL
Background/Purpose: Giant Cell Arteritis (GCA) poses challenges in clinical practice, necessitating a deep understanding. Internal medicine residents play a crucial role in patient care and…
Abstract Number: 2402 • ACR Convergence 2023
A Retrospective Analysis of Prevalence of Positive Temporal Artery Biopsies in African American Patients with Giant Cell Arteritis (GCA) in a Large Academic Health Center
Leen Al saleh¹, Haya Haddad², sunita Dia³ and Florina Constantinescu², ¹Medstar Washington Hospital Center, Alexandria, VA, ²Medstar Washington Hospital Center, Washington, DC, ³Spartanburg Regional Healthcare System, Greenville, SC
Background/Purpose: Giant Cell Arteritis (GCA) is a systemic vasculitis reportedly more common in Caucasian older adults. Studies suggest that GCA is very rare in African…
Abstract Number: 2420 • ACR Convergence 2023
Sex Differences in Giant Cell Arteritis: Data from the ARTESER Registry
Delia Fernández-Lozano¹, Marta Domínguez², Javier Narvaez³, Noemi Garrido-Puñal⁴, Eugenio De Miguel⁵, Paula V. Estrada-Alarcón⁶, Iñigo Hernández-Rodríguez⁷, Maria. T Silva-Diaz⁸, Joaquín M. Belzunegui⁹, Clara Moriano Morales¹⁰, Julio Sanchez Martin¹¹, Itziar Calvo-Zorrilla¹², Vicente Aldasoro¹³, lydia Abasolo¹⁴, Javier Loricera¹¹, Patricia Moya¹⁵, Maria J. García-Villanueva¹⁶, Carles Galisteo¹⁷, Anne Riveros-Frutos¹⁸, Francisco Ortiz-Sanjuán¹⁹, Selene Labrada-Arrabal²⁰, Margarida Rocha²¹, Carlos García-Porrúa²², Maria García-González²³, Clara Molina Almela²⁴, María Alcalde²⁵, Antonio Juan Mas²⁶, Fernando Alonso²⁷, Santos Castañeda²⁸, Ricardo Blanco²⁹ and on behalf of the Collaborative Group members³⁰, ¹Hospital de Mérida, Merida, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ⁷Hospital do Meixoeiro. Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁹Hospital Universitario Donostia, Donostia, Spain, ¹⁰Rheumatology, Hospital Universitario de León, León, Spain, ¹¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹²Basurto University Hospital, Bilbao, Spain, ¹³Hospital Universitario de Navarra, Pamplona, Spain, ¹⁴Hospital Clínico San Carlos, Madrid, Spain, ¹⁵Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ¹⁶Hospital Ramón y Cajal, Madrid, Spain, ¹⁷Hospital Universitario Parc Taulí, Sabadell, Spain, ¹⁸Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ¹⁹Hospital Universitario y Politécnico La Fe, Valencia, Spain, ²⁰Hospital del Mar, Barcelona, Spain, ²¹Osakidetza, Bilbo, Spain, ²²Hospital Universitario Lucus Augusti, Lugo, Spain, ²³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²⁴Hospital General de Valencia, Valencia, Spain, ²⁵Hospital Severo Ochoa, Madrid, Spain, ²⁶Hospital Universitario Son Llàtzer, Mallorca, Spain, ²⁷Spanish Society of Rheumatology, Madrid, Spain, ²⁸Hospital Universitario de la Princesa, Madrid, Spain, ²⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁰ARTESER group, Madrid, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in North America and Western Europe. GCA is more likely to occur in women (1).…
Abstract Number: 1049 • ACR Convergence 2023
Enhanced Diagnostic Confidence with High Frequency Temporal Artery Ultrasound in Diagnosis of Cranial Giant Cell Arteritis (GCA)
Jem Ninan¹, Suellen Lyne¹, Julian McNeil², Joanna Tieu³, Vidya Limaye⁴, Susanna Proudman⁴, Susan Lester³ and Catherine Hill³, ¹University of Adelaide, Adelaide, Australia, ²Modbury Hospital, Modbury, Australia, ³The Queen Elizabeth Hospital, Woodville, Australia, ⁴Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: A previous survey of Australian Rheumatologists indicated low confidence (60% of Australian Rheumatologists) in the use of Temporal artery ultrasound provided by their Radiology…
Abstract Number: 2373 • ACR Convergence 2023
SIRPα Expression in Systemic Vasculitis
Shubhasree Banerjee¹, Eileen Rose², Sandip Panicker², Nader Khalidi³, Curry Koening⁴, Carol Langford⁵, Paul Monach⁶, Christian Pagnoux⁷, Carol McAlear¹ and Peter Merkel¹, ¹University of Pennsylvania, Philadelphia, PA, ²Electra Therapeutics, Inc., South San Francisco, CA, ³McMaster University, Hamilton, ON, Canada, ⁴University of Texas Dell Medical School, Austin, TX, ⁵Cleveland Clinic, Cleveland, OH, ⁶VA Boston Healthcare System, Boston, MA, ⁷Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Signal regulatory protein alpha (SIRPα) is primarily found on myeloid cells, including macrophages and neutrophils. Upon binding to CD47, SIRPa signaling regulates various cellular…
Abstract Number: 2403 • ACR Convergence 2023
Systole and Diastole Ultrasound Wall Thickness Shows Significant Differences That Affect the Diagnosis and Assessment of Giant Cell Arteritis
Emma Brugarolas¹, Elisa Fernandez-Fernandez², Irene Monjo³ and Eugenio De Miguel⁴, ¹Hospital Universitari de Bellvitge, Girona, Spain, ²La Paz University Hospital, Madrid, Spain, ³University Hospital La Paz, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: In the last few years, several cut-off points for the intima-media thickness (IMT) of temporal arteries (TA) and large vessels (LV) have been proposed…
Abstract Number: 2421 • ACR Convergence 2023
Optic Nerve Sheath Measurement on Ultrasound: A Novel Diagnostic Test for Giant Cell Arteritis
Hussein Baalbaki¹, David Dube¹, Carolyn Ross², Stephanie Ducharme-Benard³, Samer Hussein⁴, Rosalie-Selene Meunier⁴, Christian Pagnoux⁵ and Jean-Paul Makhzoum², ¹Hopital du Sacre-Coeur de Montreal, University of Montreal, Montreal, QC, Canada, ²Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ³Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁴Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁵Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Confirming the diagnosis of giant cell arteritis (GCA) remains challenging. Available diagnostic tests have limited accuracy and availability. Recently, optic nerve sheath enhancement on…

« Previous Page
1
…
7
8
9
10
11
…
32
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.